Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Stephanie Vairy, Julia Lopes Garcia, Pierre Teira & Henrique Bittencourt. (2018) CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Design, Development and Therapy 12, pages 3885-3898.
Read now
Read now
Articles from other publishers (19)
Sabine Karam, Mohamad Haidous, Virginie Royal & Nelson Leung. (2023) Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney International 103:3, pages 473-484.
Crossref
Crossref
Yasaman Nazerian, Mobina Ghasemi, Younes Yassaghi, Amirhossein Nazerian & Seyed Mahmoud Hashemi. (2022) Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. International Immunopharmacology 113, pages 109428.
Crossref
Crossref
Theodora Kalpachidou, Lydia Riehl, Clemens L. Schöpf, Buket Ucar & Michaela Kress. (2022) Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain. Pain 163:S1, pages S79-S98.
Crossref
Crossref
Viva J. Rasé, Reid Hayward, James M. Haughian & Nicholas A. Pullen. (2022) Th17, Th22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma. International Journal of Molecular Sciences 23:18, pages 10299.
Crossref
Crossref
Daniela Baracaldo-Santamaría, Giovanna María Barros-Arias, Felipe Hernández-Guerrero, Alejandra De-La-Torre & Carlos-Alberto Calderon-Ospina. (2022) Immune-related adverse events of biological immunotherapies used in COVID-19. Frontiers in Pharmacology 13.
Crossref
Crossref
Frits van Rhee, Adam Rosenthal, Karan Kanhai, Rabecka Martin, Katherine Nishimura, Antje Hoering & David C. Fajgenbaum. (2022) Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Advances 6:16, pages 4773-4781.
Crossref
Crossref
Robert H. Jenkins, Stuart T.O. Hughes, Ana Cardus Figueras & Simon A. Jones. (2021) Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine 148, pages 155684.
Crossref
Crossref
Antonino Carbone, Margaret Borok, Blossom Damania, Annunziata Gloghini, Mark N. Polizzotto, Raj K. Jayanthan, David C. Fajgenbaum & Mark Bower. (2021) Castleman disease. Nature Reviews Disease Primers 7:1.
Crossref
Crossref
Annalisa Marcuzzi, Elisabetta Melloni, Giorgio Zauli, Arianna Romani, Paola Secchiero, Natalia Maximova & Erika Rimondi. (2021) Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity. International Journal of Molecular Sciences 22:20, pages 11241.
Crossref
Crossref
Benjamin Koa, Austin J. Borja, Mahmoud Aly, Sayuri Padmanabhan, Joseph Tran, Vincent Zhang, Chaitanya Rojulpote, Sheila K. Pierson, Mark-Avery Tamakloe, Johnson S. Khor, Thomas J. Werner, David C. Fajgenbaum, Abass Alavi & Mona-Elisabeth Revheim. (2021) Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights into Imaging 12:1.
Crossref
Crossref
Yuejuan Pan, Zhuan Cui, Song Wang, Danxia Zheng, Zhenling Deng, Xinyu Tian, Hongxia Guo, Wenhan Bao, Sijia Zhou & Yue Wang. (2020) Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature. BMC Nephrology 21:1.
Crossref
Crossref
Bettina Klug, Barbara Schnierle & Isabel Trebesch. (2020) Monoklonale Antikörper zur antiinfektiven TherapieMonoclonal antibodies for anti-infective therapy. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 63:11, pages 1396-1402.
Crossref
Crossref
Atreyee Borthakur, Yogamaya D Prabhu & Abilash Valsala Gopalakrishnan. (2020) Role of IL-6 signalling in Polycystic Ovarian Syndrome associated inflammation. Journal of Reproductive Immunology 141, pages 103155.
Crossref
Crossref
Uddalak Bharadwaj, Moses M. Kasembeli, Prema Robinson & David J. Tweardy. (2020) Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacological Reviews 72:2, pages 486-526.
Crossref
Crossref
Frits van Rhee, Corey Casper, Peter M Voorhees, Luis E Fayad, Damilola Gibson, Karan Kanhai & Razelle Kurzrock. (2020) Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. The Lancet Haematology 7:3, pages e209-e217.
Crossref
Crossref
Zi Ying Li, Shirley Kim, SiYi Huang & Raza Mian. (2019) Multicentric Castleman disease with TAFRO syndrome and Sjögren's. Clinical Case Reports 7:12, pages 2388-2392.
Crossref
Crossref
E. A. Gorshkova, R. V. Zvartsev, M. S. Drutskaya & E. O. Gubernatorova. (2019) Humanized Mouse Models as a Tool to Study Proinflammatory Cytokine Overexpression. Molecular Biology 53:5, pages 665-680.
Crossref
Crossref
Sisi Cai, Zhaodong Zhong, Xiang Li, Hong Xiang Wang, Li Wang & Min Zhang. (2019) Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids. Medicine 98:46, pages e17681.
Crossref
Crossref
Ali Berkant Avci, Eugen Feist & Gerd Rüdiger Burmester. (2018) Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?. BioDrugs 32:6, pages 531-546.
Crossref
Crossref